PLX - Protalix BioTherapeutics Inc Stock Price, Fair Value and News

$1.75+0.01 (+0.57%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

PLX Price Action

Last 7 days

-2.8%

Last 30 days

3.6%

Last 90 days

59.1%

Trailing 12 Months

0.6%

PLX RSI Chart

PLX Valuation

Market Cap

128.9M

Price/Earnings (Trailing)

-13.41

Price/Sales (Trailing)

2.82

EV/EBITDA

-15

Price/Free Cashflow

17.97

PLX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PLX Fundamentals

PLX Revenue

Revenue (TTM)

45.7M

Rev. Growth (Yr)

73.6%

Rev. Growth (Qtr)

33.29%

PLX Earnings

Earnings (TTM)

-9.6M

Earnings Growth (Yr)

274.73%

Earnings Growth (Qtr)

246.89%

PLX Profitability

Operating Margin

35.86%

EBT Margin

-21.00%

Return on Equity

-29.61%

Return on Assets

-15.6%

Free Cashflow Yield

5.57%

PLX Investor Care

Shares Dilution (1Y)

0.93%

Diluted EPS (TTM)

-0.11

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	59.7M	38.1M	45.7M	0
2023	41.1M	67.5M	63.6M	65.5M
2022	43.1M	45.4M	47.6M	47.6M
2021	52.6M	48.0M	49.3M	38.4M
2020	65.9M	64.6M	61.2M	62.9M
2019	40.1M	50.4M	64.0M	54.7M
2018	22.7M	18.4M	11.5M	34.2M
2017	11.4M	16.0M	18.9M	21.1M
2016	3.4M	3.8M	7.1M	9.2M
2015	3.7M	3.9M	4.2M	4.4M
2014	13.6M	13.8M	13.9M	3.5M
2013	34.6M	10.7M	9.3M	10.5M
2012	8.1M	33.5M	36.1M	34.9M
2011	9.6M	9.3M	7.2M	8.4M
2010	0	2.5M	4.6M	6.6M
2009	0	0	0	388.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Protalix BioTherapeutics Inc

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; FundaÃƒÆ’Ã‚Â§ÃƒÆ’Ã‚Â£o Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

CEO	Mr. Dror Bashan
WEBSITE	protalix.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	193

Protalix BioTherapeutics Inc Frequently Asked Questions

What is the ticker symbol for Protalix BioTherapeutics Inc? What does PLX stand for in stocks?

PLX is the stock ticker symbol of Protalix BioTherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Protalix BioTherapeutics Inc (PLX)?

As of Fri Dec 20 2024, market cap of Protalix BioTherapeutics Inc is 128.86 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PLX stock?

You can check PLX's fair value in chart for subscribers.

Is Protalix BioTherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PLX is over valued or under valued. Whether Protalix BioTherapeutics Inc is cheap or expensive depends on the assumptions which impact Protalix BioTherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PLX.

What is Protalix BioTherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, PLX's PE ratio (Price to Earnings) is -13.41 and Price to Sales (PS) ratio is 2.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PLX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Protalix BioTherapeutics Inc's stock?

In the past 10 years, Protalix BioTherapeutics Inc has provided -0.21 (multiply by 100 for percentage) rate of return.